


**IN THE CLAIMS:**


Kindly amend the application without prejudice, without admission, without surrender of subject matter, and without any intention of creating any estoppel as to equivalents, as follows:

1. (Currently Amended) A compound ~~having Formula I~~



Formula I

having Formula VIII




Formula VIII

wherein G is H, OH or a ~~substituent~~ hydrocarbyl group, and wherein R¹ is any one of a sulphamate group, a phosphonate group, a thiophosphonate group, a sulphonate group or a sulphonamide group.

- 2-7. (Canceled)

8. (Original) A compound according to claim 1 having Formula XII



Formula XII

9. (Currently Amended) A compound according to claim 1 wherein ~~the G is H, OH~~ or a hydrocarbyl group is selected from the group consisting of an optionally substituted hydrocarbon group, an optionally substituted alkyl group, an optionally substituted haloalkyl group, an aryl group, an alkylaryl group, an alkylarylalkyl group and an alkene group.


10-11. (Canceled)

12. (Currently Amended) A compound according to claim 1 wherein ~~G or the~~ hydrocarbyl group is selected from the group consisting essentially of:

a C<sub>1</sub>-C<sub>10</sub> alkyl group, a C<sub>1</sub>-C<sub>6</sub> alkyl group, a C<sub>1</sub>-C<sub>3</sub> alkyl group;  
C<sub>1</sub>-C<sub>10</sub> haloalkyl group, a C<sub>1</sub>-C<sub>6</sub> haloalkyl group, a C<sub>1</sub>-C<sub>3</sub> haloalkyl group;  
C<sub>1</sub>-C<sub>10</sub> bromoalkyl group, C<sub>1</sub>-C<sub>6</sub> bromoalkyl group, C<sub>1</sub>-C<sub>3</sub> bromoalkyl group;  
-(CH<sub>2</sub>)<sub>1-10</sub> aryl, -(CH<sub>2</sub>)<sub>1-10</sub>-Ph, (CH<sub>2</sub>)<sub>1-10</sub>-Ph-C<sub>1-10</sub> alkyl, -(CH<sub>2</sub>)<sub>1-5</sub>-Ph, (CH<sub>2</sub>)<sub>1-5</sub>-Ph-C<sub>1-5</sub>  
alkyl, -(CH<sub>2</sub>)<sub>1-3</sub>-Ph, (CH<sub>2</sub>)<sub>1-3</sub>-Ph-C<sub>1-3</sub> alkyl, -CH<sub>2</sub>-Ph, -CH<sub>2</sub>-Ph-C(CH<sub>3</sub>)<sub>3</sub>, -(CH<sub>2</sub>)<sub>1-10</sub> cycloalkyl, -  
(CH<sub>2</sub>)<sub>1-10</sub>-C<sub>3-10</sub>cycloalkyl, -(CH<sub>2</sub>)<sub>1-7</sub>-C<sub>3-7</sub>cycloalkyl, -(CH<sub>2</sub>)<sub>1-5</sub>-C<sub>3-5</sub>cycloalkyl, -(CH<sub>2</sub>)<sub>1-3</sub>-C<sub>3-</sub>  
5cycloalkyl, -CH<sub>2</sub>-C<sub>3</sub>cycloalkyl; and,  
an alkene, a C<sub>1</sub>-C<sub>10</sub> alkene group, a C<sub>1</sub>-C<sub>6</sub> alkene group, a C<sub>1</sub>-C<sub>3</sub> alkene group.


13-17. (Canceled)

18. (Original) A compound according to claim 1 wherein G is H.
19. (Original) A compound according to claim 1 wherein R<sup>1</sup> is a sulphamate group.
20. (Currently Amended) A compound according to claim 1 wherein R<sup>1</sup> or the sulphamate group is of the formula



wherein R<sup>4</sup> and R<sup>5</sup> are independently selected from H, alkyl, cycloalkyl, alkenyl and aryl, or combinations thereof, or together represent alkylene, wherein the alkylene or each alkyl or cycloalkyl or alkenyl or aryl optionally contain one or more hetero atoms or groups.


21. (Original) A compound according to claim 20 wherein at least one of R<sup>4</sup> and R<sup>5</sup> is H.
22. (Original) A compound according to claim 21 wherein R<sup>4</sup> and R<sup>5</sup> are H.
23. (Currently Amended) A compound according to claim 1 having Formula XII



Formula XII

wherein G is selected from H, OH, C<sub>1</sub>-C<sub>10</sub> alkyl, C<sub>1</sub>-C<sub>10</sub> haloalkyl, -(CH<sub>2</sub>)<sub>1-10</sub>-aryl, -(CH<sub>2</sub>)<sub>1-10</sub>-cycloalkyl, and C<sub>1</sub>-C<sub>10</sub> alkene;

wherein R<sup>1</sup> is OH or a sulphamate group of the formula



wherein R<sup>4</sup> and R<sup>5</sup> are independently selected from H, alkyl, cycloalkyl, alkenyl and aryl, or combinations thereof, or together represent alkylene, wherein the alkylene or each alkyl or cycloalkyl or alkenyl or aryl optionally contain one or more hetero atoms or groups.

24. (Original) A pharmaceutical composition comprising a compound according to claim 1 optionally admixed with a pharmaceutically acceptable carrier, diluent, excipient or adjuvant.

25-29. (Canceled)

30. (Currently Amended) A method comprising (a) performing a steroid sulphatase assay with one or more candidate compounds having the formula as defined in claim 1; (b) determining whether one or more of said candidate compounds is/are capable of ~~modulating~~ stimulating STS steroid sulphatase activity; and (c) selecting one or more of said candidate compounds that is/are capable of ~~modulating~~ stimulating STS steroid sulphatase activity.

31. (Currently Amended) A method comprising (a) performing a steroid sulphatase assay with one or more candidate compounds having the formula as defined in claim 1; (b) determining whether one or more of said candidate compounds is/are capable of inhibiting STS steroid sulphatase; and (c) selecting one or more of said candidate compounds that is/are capable of inhibiting STS steroid sulphatase activity.

32. (Original) A compound identified by the method according to claim 30.

33. (Original) A compound identified by the method according to claim 31.

34-35. (Cancelled)

36. (Original) A pharmaceutical composition comprising the compound according to claim 32 optionally admixed with a pharmaceutically acceptable carrier, diluent, excipient or adjuvant.

37. (Original) A pharmaceutical composition comprising the compound according to claim 33 optionally admixed with a pharmaceutically acceptable carrier, diluent, excipient or adjuvant.

38-41. (Cancelled)

42. (New) The method of claim 30, wherein the candidate compound is capable of inhibiting STS activity.

43. (New) A method of treating a condition or disease associated with steroid sulphatase activity, comprising administering a compound according to claim 1 to a subject in need thereof.

44. (New) A method of treating a condition or disease associated with steroid sulphatase activity, comprising administering a compound according to claim 32 to a subject in need thereof.

45. (New) A method of treating a condition or disease associated with steroid sulphatase activity, comprising administering a compound according to claim 33 to a subject in need thereof.

46. (New) A method of manufacturing a medicament for therapy of a condition or disease associated with steroid sulphatase, comprising admixing the compound according to claim 1 with a pharmaceutically acceptable carrier, diluent, excipient or adjuvant.

47. (New) A method of manufacturing a medicament for therapy of a condition or disease associated with steroid sulphatase, comprising admixing the compound according to claim 32 with a pharmaceutically acceptable carrier, diluent, excipient or adjuvant.

48. (New) A method of manufacturing a medicament for therapy of a condition or disease associated with steroid sulphatase, comprising admixing the compound according to claim 33 with a pharmaceutically acceptable carrier, diluent, excipient or adjuvant.

49. (New) A method of manufacturing a medicament for therapy of a condition or disease associated with adverse steroid sulphatase levels, comprising admixing the compound according to claim 1 with a pharmaceutically acceptable carrier, diluent, excipient or adjuvant.

50. (New) A method of manufacturing a medicament for therapy of a condition or disease associated with adverse steroid sulphatase levels, comprising admixing the compound according to claim 32 with a pharmaceutically acceptable carrier, diluent, excipient or adjuvant.

51. (New) A method of manufacturing a medicament for therapy of a condition or disease associated with adverse steroid sulphatase levels, comprising admixing the compound according to claim 33 with a pharmaceutically acceptable carrier, diluent, excipient or adjuvant.

52. (New) A method of manufacturing a pharmaceutical for inhibiting steroid sulphatase activity, comprising admixing the compound according to claim 1 with a pharmaceutically acceptable carrier, diluent, excipient or adjuvant.

53. (New) A method of manufacturing a pharmaceutical for inhibiting steroid sulphatase activity, comprising admixing the compound according to claim 32 with a pharmaceutically acceptable carrier, diluent, excipient or adjuvant.

54. (New) A method of manufacturing a pharmaceutical for inhibiting steroid sulphatase activity, comprising admixing the compound according to claim 33 with a pharmaceutically acceptable carrier, diluent, excipient or adjuvant.